The purpose of this study is to evaluate the safety and efficacy of topiramate in reducing
drinking and heavy drinking frequency in problem drinkers. We hypothesize that at a dosage of
up to 200mg/day, topiramate will be well tolerated in this patient population and that,
compared to placebo treatment, topiramate will result in a greater reduction in the frequency
of both drinking days and heavy drinking days.
Phase:
Phase 4
Details
Lead Sponsor:
UConn Health
Collaborators:
National Center for Research Resources (NCRR) National Institute on Alcohol Abuse and Alcoholism (NIAAA)